All In Biotech

Drug Trial Radar · NCT03323671

Preemptive Analgesia for Primary Dysmenorrhoea

Preemptive Analgesia for Primary Dysmenorrhoea: a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Aug 1, 2017

Primary completion

Dec 1, 2017

Study completion Dec 1, 2017

Sponsor

Lead sponsor
Hanan NabilAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
Female only, from 15 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Preemptive analgesia before the release of pain mediators

Conditions

  • Primary Dysmenorrhea

Interventions

  • preemptive mefenamic acidDrug

    preemptive analgesia before menstrual pain

  • mefenamic acidDrug

    mefenamic acid given only during menstruation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in the Degree of painTime frame: 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mansoura University

    Al Mansurah, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.